Prigann J, Tavora R, Furler O’Brien RL, Schulze-Gahmen U, Boehm D, Roan NR, Nixon DF, Ndhlovu LC, Valente S, Ott M.
2024 Oct;9(10):2470-2472. doi: 10.1038/s41564-024-01816-5. PMID: 39289508.
Publication Category: HIV/AIDS
CRISPR-Cas9 screen of E3 ubiquitin ligases identifies TRAF2 and UHRF1 as regulators of HIV latency in primary human T cells.
Rathore U, Haas P, Easwar Kumar V, Hiatt J, Haas KM, Bouhaddou M, Swaney DL, Stevenson E, Zuliani-Alvarez L, McGregor MJ, Turner-Groth A, Ochieng’ Olwal C, Bediako Y, Braberg H, Soucheray M, Ott M, Eckhardt M, Hultquist JF, Marson A, Kaake RM, Krogan NJ.
2024 Feb 27:e0222223. doi: 10.1128/mbio.02222-23. Epub ahead of print. PMID: 38411080.
Protocol for an in vitro assay to study HIV-1 Tat methylation
Boehm D, Kaehlcke K, Schnoelzer M, Ott M.
2023 Nov 17;4(4):102687. doi: 10.1016/j.xpro.2023.102687. Epub ahead of print. PMID: 37979180.
A flow cytometry-based assay to investigate HIV-1 expression in SMYD5 shRNA containing primary CD4+ T cells
Boehm D, Ott M.
STAR Protoc. 2023 Nov 4;4(4):102694. doi: 10.1016/j.xpro.2023.102694. Epub ahead of print. PMID: 37925635.
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing
Lyons DE, Kumar P, Roan NR, Defechereux PA, Feschotte C, Lange UC, Murthy N, Sameshima P, Verdin E, Ake JA, Parsons MS, Nath A, Gianella S, Smith DM, Kallas EG, Villa TJ, Strange R, Mwesigwa B, Furler O’Brien RL, Nixon DF, Ndhlovu LC, Valente ST, Ott M.
2023 Oct 28;15(11):2171. doi: 10.3390/v15112171. PMID: 38005849; PMCID: PMC10674359.
Comprehensive synergy mapping links a BAF- and NSL-containing “supercomplex” to the transcriptional silencing of HIV-1
Li Z, Deeks SG, Ott M, Greene WC.
2023 Sep 26;42(9):113055. doi: 10.1016/j.celrep.2023.113055. Epub 2023 Sep 7. PMID: 37682714; PMCID: PMC10591912.
The lysine methyltransferase SMYD5 amplifies HIV-1 transcription and is post-transcriptionally upregulated by Tat and USP11.
Boehm D, Lam V, Schnolzer M, Ott M.
2023 Mar 28;42(3):112234. doi: 10.1016/j.celrep.2023.112234. Epub 2023 Mar 9. PMID: 36897778; PMCID: PMC10124996.
Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity Ex Vivo and In Vivo.
Gramatica A, Schwarzer R, Brantley W, Varco-Merth B, Sperber HS, Hull PA, Montano M, Migueles SA, Rosenthal D, Hogan LE, Johnson JR, Packard TA, Grimmett ZW, Herzig E, Besnard E, Nekorchuk M, Hsiao F, Deeks SG, Snape M, Kiernan B, Roan NR, Lifson JD, Estes JD, Picker LJ, Verdin E, Krogan NJ, Henrich TJ, Connors M, Ott M, Pillai SK, Okoye AA, Greene WC.
doi: 10.1128/JVI.02393-20.
FOXO1 promotes HIV latency by suppressing ER stress in T cells.
Vallejo-Gracia A, Chen IP, Perrone R, et al. [published online ahead of print, 2020 Jun 15]. Nat Microbiol. 2020;10.1038/s41564-020-0742-9. doi:10.1038/s41564-020-0742-9
Turning up the heat on HIV-1.
Chen IP, Ott M. [published online ahead of print, 2020 Jun 30]. Proc Natl Acad Sci U S A. 2020;202010212. doi:10.1073/pnas.2010212117